Drugs / CVN058
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03669250 Comparator | Nov 2018 → Mar 2020 | schizophrenia | Cerevance Alpha, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-16 | Cerevance Beta, Inc. | Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study cerevance.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVN058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03669250 ↗ |
| Route | Oral | “a single oral administration of CVN058 (15 mg or 150 mg)” NCT03669250 ↗ |